{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T17:14:17Z","timestamp":1776532457087,"version":"3.51.2"},"reference-count":92,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.beem.2018.05.007","type":"journal-article","created":{"date-parts":[[2018,5,26]],"date-time":"2018-05-26T12:37:18Z","timestamp":1527338238000},"page":"759-772","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":59,"title":["Update on osteoporosis in men"],"prefix":"10.1016","volume":"32","author":[{"given":"Robert A.","family":"Adler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.beem.2018.05.007_bib1","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1002\/jbmr.2202","article-title":"Osteoporosis medication use after hip fracture in U.S. patients between 2002 and 2011","volume":"29","author":"Solomon","year":"2014","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.beem.2018.05.007_bib2","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.semarthrit.2014.09.011","article-title":"Analysis of quality improvement efforts in preventing glucocorticoid-induced osteoporosis","volume":"44","author":"Tory","year":"2015","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.beem.2018.05.007_bib3","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1111\/j.1532-5415.2010.02769.x","article-title":"Missed opportunities for osteoporosis treatment in patients hospitalized for hip fracture","volume":"58","author":"Jennings","year":"2010","journal-title":"J\u00a0Am Geriatr Soc"},{"key":"10.1016\/j.beem.2018.05.007_bib4","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/BF03346716","article-title":"Glucocorticoid-induced osteoporosis in men","volume":"34","author":"Adler","year":"2011","journal-title":"J\u00a0Endocrinol Invest"},{"key":"10.1016\/j.beem.2018.05.007_bib5","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1007\/s00198-011-1652-8","article-title":"Estimation of the lifetime risk of hip fracture for women and men in Canada","volume":"23","author":"Hopkins","year":"2012","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.beem.2018.05.007_bib6","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1007\/s00198-013-2561-9","article-title":"Fracture risk among older men: osteopenia and osteoporosis defined using cut-points derived from female versus male reference data","volume":"25","author":"Pasco","year":"2014","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.beem.2018.05.007_bib7","doi-asserted-by":"crossref","first-page":"g4120","DOI":"10.1136\/bmj.g4120","article-title":"Implications of expanding indications for drug treatment to prevent fracture in older men in United States: cross sectional and longitudinal analysis of prospective cohort study","volume":"349","author":"Ensrud","year":"2014","journal-title":"BMJ"},{"key":"10.1016\/j.beem.2018.05.007_bib8","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1007\/s00198-014-2655-z","article-title":"The clinical diagnosis of osteoporosis: a position statement from the National Bone Health Alliance Working Group","volume":"25","author":"Siris","year":"2014","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.beem.2018.05.007_bib9","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1007\/s00198-012-2215-3","article-title":"Performance of FRAX in a cohort of community-dwelling, ambulatory older men: the Osteoporotic Fractures in Men (MrOS) study","volume":"24","author":"Ettinger","year":"2013","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.beem.2018.05.007_bib10","doi-asserted-by":"crossref","first-page":"e107695","DOI":"10.1371\/journal.pone.0107695","article-title":"External validation of the Garvan nomograms for predicting absolute fracture risk: the Tromso study","volume":"9","author":"Ahmed","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.beem.2018.05.007_bib11","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s00198-007-0550-6","article-title":"Cost-effective osteoporosis treatment thresholds: the United States perspective","volume":"19","author":"Tosteson","year":"2008","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.beem.2018.05.007_bib12","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1007\/s00198-016-3865-3","article-title":"The impact of the new National Bone Health Alliance (NBHA) diagnostic criteria on the prevalence of osteoporosis in the USA","volume":"28","author":"Wright","year":"2017","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.beem.2018.05.007_bib13","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1002\/jbmr.2849","article-title":"Objectively verified parental hip fracture is an independent risk factor for fracture: a linkage analysis of 478,792 parents and 261,705 offspring","volume":"31","author":"Yang","year":"2016","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.beem.2018.05.007_bib14","article-title":"Falls predict fractures independently of FRAX probability: a meta-analysis of the osteoporotic fractures in men (MrOS) study","author":"Harvey","year":"2017","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.beem.2018.05.007_bib15","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1007\/s00198-008-0712-1","article-title":"Case finding for the management of osteoporosis with FRAX \u2013 assessment and intervention thresholds for the UK","volume":"19","author":"Kanis","year":"2008","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.beem.2018.05.007_bib16","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1007\/s11606-017-4153-4","article-title":"Screening for osteoporosis in older men: operating characteristics of proposed strategies for selecting men for BMD testing","volume":"32","author":"Diem","year":"2017","journal-title":"J\u00a0Gen Intern Med"},{"key":"10.1016\/j.beem.2018.05.007_bib17","doi-asserted-by":"crossref","first-page":"356","DOI":"10.7326\/0003-4819-154-5-201103010-00307","article-title":"Screening for osteoporosis: U.S. preventive services task force recommendation statement","volume":"154","author":"US Preventive Services Task Force","year":"2011","journal-title":"Ann Intern Med"},{"issue":"Suppl 1","key":"10.1016\/j.beem.2018.05.007_bib18","article-title":"Primary osteoporosis screening in U.S. male veterans is effective in high risk subgroups, but not overall","volume":"32","author":"Colon-Emeric","year":"2017","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.beem.2018.05.007_bib19","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1177\/1759720X15621227","article-title":"Osteoporosis in men: findings from the osteoporotic fractures in men study (MrOS)","volume":"8","author":"Cawthon","year":"2016","journal-title":"Ther Adv Musculoskel Dis"},{"key":"10.1016\/j.beem.2018.05.007_bib20","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1002\/jbmr.2836","article-title":"Risk factors for hip fracture in older men: the osteoporotic fractures in men study (MrOS)","volume":"31","author":"Cauley","year":"2016","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.beem.2018.05.007_bib21","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJM198606263142605","article-title":"Involutional osteoporosis","volume":"314","author":"Riggs","year":"1986","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beem.2018.05.007_bib22","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1210\/jcem.86.2.7219","article-title":"Longitudinal effects of aging on serum total and free testosterone levels in healthy men","volume":"86","author":"Harman","year":"2001","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2018.05.007_bib23","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1177\/1759720X11411600","article-title":"Osteoporosis in men: insights for the clinician","volume":"3","author":"Adler","year":"2011","journal-title":"Ther Adv Musculoskel Dis"},{"key":"10.1016\/j.beem.2018.05.007_bib24","doi-asserted-by":"crossref","first-page":"4949","DOI":"10.1210\/jc.2003-032081","article-title":"Perturbed sex steroid status in men with idiopathic osteoporosis and their sons","volume":"89","author":"van Pottelbergh","year":"2004","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2018.05.007_bib25","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1210\/jcem.83.7.4964","article-title":"An association between serum IGF-I and a simple sequence repeat in the IGF-I gene: implications for genetic studies of bone mineral density","volume":"83","author":"Rosen","year":"1998","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2018.05.007_bib26","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1210\/jcem.82.8.4163","article-title":"Long-term effect of testosterone on bone mineral density in hypogonadal men","volume":"82","author":"Behre","year":"1997","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2018.05.007_bib27","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1001\/jamainternmed.2016.9539","article-title":"Effect of testosterone treatment on volumetric bone density and strength in older men with low testosterone. A controlled clinical trial","volume":"177","author":"Snyder","year":"2017","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.beem.2018.05.007_bib28","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1007\/s11914-012-0120-5","article-title":"Idiopathic hypercalciuria and bone health","volume":"10","author":"Ryan","year":"2012","journal-title":"Curr Osteoporos Rep"},{"key":"10.1016\/j.beem.2018.05.007_bib29","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S0025-6196(11)62214-3","article-title":"Secondary causes of osteoporosis","volume":"77","author":"Fitzpatrick","year":"2002","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.beem.2018.05.007_bib30","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/j.clinbiochem.2012.01.024","article-title":"Laboratory testing for secondary osteoporosis evaluation","volume":"45","author":"Adler","year":"2012","journal-title":"Clin Biochem"},{"key":"10.1016\/j.beem.2018.05.007_bib31","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1007\/s00198-010-1421-0","article-title":"Osteoporosis in men: the value of laboratory testing","volume":"22","author":"Ryan","year":"2011","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.beem.2018.05.007_bib32","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s00198-015-3356-y","article-title":"Clinical utility of routine laboratory testing to identify possible secondary causes in older men with osteoporosis: the Osteoporotic Fractures in Men (MrOS) Study","volume":"27","author":"Fink","year":"2016","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.beem.2018.05.007_bib33","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.1210\/jc.2015-4106","article-title":"Low free testosterone is associated with hypogonadal signs and symptoms in men with normal total testosterone","volume":"101","author":"Antonio","year":"2016","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2018.05.007_bib34","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1210\/jc.2016-2935","article-title":"Harmonized reference ranges for circulating testosterone levels in men of four cohort studies in the United States and Europe","volume":"102","author":"Travison","year":"2017","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2018.05.007_bib35","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1210\/jcem.86.8.7736","article-title":"Relationship of serum sex steroid levels to longitudinal changes in bone density in young versus elderly men","volume":"86","author":"Khosla","year":"2001","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2018.05.007_bib36","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1053\/beem.2002.0199","article-title":"Prenatal and childhood influences on osteoporosis","volume":"16","author":"Javaid","year":"2002","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2018.05.007_bib37","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1210\/jc.2011-3045","article-title":"Osteoporosis in men: an endocrine society clinical practice guideline","volume":"97","author":"Watts","year":"2012","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2018.05.007_bib38","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1001\/jama.298.20.2381","article-title":"High-trauma fractures and low bone mineral density in older women and men","volume":"298","author":"Mackey","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.beem.2018.05.007_bib39","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1093\/rheumatology\/39.12.1383","article-title":"Oral corticosteroids and fracture risk: relationship to daily and cumulative doses","author":"van Staa","year":"2000","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.beem.2018.05.007_bib40","doi-asserted-by":"crossref","first-page":"j1415","DOI":"10.1136\/bmj.j1415","article-title":"Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study","volume":"357","author":"Waljee","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.beem.2018.05.007_bib41","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s00223-015-0044-z","article-title":"Definitions of sarcopenia: associations with previous falls and fracture in a population sample","volume":"97","author":"Clynes","year":"2015","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.beem.2018.05.007_bib42","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1007\/s00198-015-3478-2","article-title":"Thoracic kyphosis and rate of incident vertebral fractures: the Fracture Intervention Trial","volume":"27","author":"Katzman","year":"2016","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.beem.2018.05.007_bib43","article-title":"A\u00a0meta-analysis of the association between body mass index and risk of vertebral fracture","author":"Kaze","year":"2017","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.beem.2018.05.007_bib44","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1002\/jbmr.1863","article-title":"Trends in hip fracture rates in Canada: an age-period-cohort analysis","volume":"28","author":"Jean","year":"2013","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.beem.2018.05.007_bib45","article-title":"Hip fracture trends in the United States, 2002 to 2015","author":"Lewiecki","year":"2017","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.beem.2018.05.007_bib46","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1002\/jbmr.2888","article-title":"A\u00a0crisis in the treatment of osteoporosis","volume":"31","author":"Khosla","year":"2016","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.beem.2018.05.007_bib47","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1007\/s00198-009-1105-9","article-title":"Bone mineral density and prevalent osteoarthritis of the hip in older men for the Osteoporotic Fractures in Men (MrOS) Study Group","volume":"21","author":"Chaganti","year":"2010","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.beem.2018.05.007_bib48","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1359\/jbmr.1998.13.12.1915","article-title":"Bone density and fracture risk in men","volume":"13","author":"Melton","year":"1998","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.beem.2018.05.007_bib49","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.1210\/jc.2012-1569","article-title":"A\u00a0randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density","volume":"97","author":"Orwoll","year":"2012","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2018.05.007_bib50","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.urology.2005.07.017","article-title":"Prevalence of osteopenia and osteoporosis by central and peripheral bone mineral density in men with prostate cancer during androgen-deprivation therapy","volume":"67","author":"Bruder","year":"2006","journal-title":"Urology"},{"key":"10.1016\/j.beem.2018.05.007_bib51","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1056\/NEJMoa041943","article-title":"Risk of fracture after androgen deprivation for prostate cancer","volume":"352","author":"Shahinian","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beem.2018.05.007_bib52","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1210\/jc.2007-1402","article-title":"Approach to the prostate cancer patient with bone disease","volume":"93","author":"Greenspan","year":"2008","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2018.05.007_bib53","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1007\/s00198-010-1185-6","article-title":"Using clinical risk factors and bone mineral density to determine who among patients undergoing bone densitometry should have vertebral fracture assessment","volume":"21","author":"Vokes","year":"2010","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.beem.2018.05.007_bib54","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1210\/jc.2010-2704","article-title":"The 2011 report on dietary reference intakes for calcium and vitamin D from the institute of medicine: what clinicians need to know","volume":"96","author":"Ross","year":"2011","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2018.05.007_bib55","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1210\/jc.2011-0385","article-title":"Evaluation, treatment, and prevention of vitamin D deficiency: an endocrine society clinical practice guideline","volume":"96","author":"Holick","year":"2011","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2018.05.007_bib56","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1002\/jbmr.2536","article-title":"Serum 25-hydroxyvitamin D levels: variability, knowledge gaps, and the concept of a desirable range","volume":"30","author":"El-Hajj Fuleihan","year":"2015","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.beem.2018.05.007_bib57","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1056\/NEJM200008313430902","article-title":"Alendronate for the treatment of osteoporosis in men","volume":"343","author":"Orwoll","year":"2000","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beem.2018.05.007_bib58","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00296-005-0004-4","article-title":"Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study","volume":"26","author":"Ringe","year":"2006","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.beem.2018.05.007_bib59","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.bone.2009.12.034","article-title":"Efficacy and safety of monthly ibandronate in men with low bone density","volume":"46","author":"Orwoll","year":"2010","journal-title":"Bone"},{"key":"10.1016\/j.beem.2018.05.007_bib60","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1002\/jbmr.119","article-title":"Efficacy and safety of a once-yearly i.v. infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled trial","volume":"25","author":"Orwoll","year":"2010","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.beem.2018.05.007_bib61","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1056\/NEJMoa1204061","article-title":"Fracture risk and zoledronic acid therapy in men with osteoporosis","volume":"367","author":"Boonen","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beem.2018.05.007_bib62","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1359\/jbmr.0707onj","article-title":"Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research","volume":"22","author":"Khosla","year":"2007","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.beem.2018.05.007_bib63","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jbmr.1998","article-title":"Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research","volume":"29","author":"Shane","year":"2014","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.beem.2018.05.007_bib64","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.14219\/jada.archive.2011.0108","article-title":"Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: executive summary of recommendations from the American Dental Association Council on Scientific Affairs","volume":"142","author":"Hellstein","year":"2011","journal-title":"J\u00a0Am Dent Assoc"},{"key":"10.1016\/j.beem.2018.05.007_bib65","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/jbmr.2405","article-title":"Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus","volume":"30","author":"Khan","year":"2015","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.beem.2018.05.007_bib66","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJMoa1010650","article-title":"Bisphosphonate use and atypical fractures of the femoral shaft","volume":"364","author":"Schilcher","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beem.2018.05.007_bib67","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/RHU.0000000000000170","article-title":"Bisphosphonates and hip and nontraumatic subtrochanteric femoral fractures in the Veterans Health Administration","volume":"20","author":"Safford","year":"2014","journal-title":"J\u00a0Clin Rheumatol"},{"key":"10.1016\/j.beem.2018.05.007_bib68","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1056\/NEJMcp1513724","article-title":"Postmenopausal osteoporosis","volume":"374","author":"Black","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beem.2018.05.007_bib69","doi-asserted-by":"crossref","first-page":"R81","DOI":"10.1530\/EJE-17-1002","article-title":"Atypical femoral fractures: risks and benefits of long term treatment of osteoporosis with anti-resorptive therapy","volume":"178","author":"Adler","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2018.05.007_bib70","doi-asserted-by":"crossref","first-page":"e0180325","DOI":"10.1371\/journal.pone.0180325","article-title":"Randomized clinical trial comparing efficacy and safety of brand versus generic alendronate (Bonmax\u00ae)","volume":"12","author":"Unnanuntana","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.beem.2018.05.007_bib71","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","article-title":"Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX); a randomized trial","volume":"296","author":"Black","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.beem.2018.05.007_bib72","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/jbmr.1494","article-title":"The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)","volume":"27","author":"Black","year":"2012","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.beem.2018.05.007_bib73","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/jbmr.2708","article-title":"Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a task force of the American Society for Bone and Mineral Research","volume":"31","author":"Adler","year":"2016","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.beem.2018.05.007_bib74","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1002\/art.40137","article-title":"2\u201317 American College of Rheumatology Guideline for the prevention and treatment of glucocorticoid-induced osteoporosis","volume":"69","author":"Buckley","year":"2017","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.beem.2018.05.007_bib75","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/s12020-015-0748-x","article-title":"Duration of anti-resorptive therapy for osteoporosis","volume":"51","author":"Adler","year":"2016","journal-title":"Endocrine"},{"key":"10.1016\/j.beem.2018.05.007_bib76","doi-asserted-by":"crossref","first-page":"818","DOI":"10.7326\/M15-1361","article-title":"Clinical Guidelines Committee of the American College of Physicians. Treatment of bow bone density or osteoporosis to prevent fractures in men and women: a clinical practice guideline update from the American College of Physicians","volume":"166","author":"Qaseem","year":"2017","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.beem.2018.05.007_bib77","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.bone.2015.11.021","article-title":"Proportion of osteoporotic women remaining at risk for fracture despite adherence to oral bisphosphonates","volume":"83","author":"Imel","year":"2016","journal-title":"Bone"},{"key":"10.1016\/j.beem.2018.05.007_bib78","doi-asserted-by":"crossref","first-page":"i3365","DOI":"10.1136\/bmj.i3365","article-title":"Risk of hip, subtrochanteric, and femoral shaft fractures among mid and long term users of alendronate: nationwide cohort and nested case-control study","volume":"353","author":"Abrahamsen","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.beem.2018.05.007_bib79","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1210\/jc.2014-4079","article-title":"A\u00a024-month study evaluating the efficacy and safety of denosumab for the treatment of men with low bone mineral density: results from the ADAMO trial","volume":"100","author":"Langdahl","year":"2015","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2018.05.007_bib80","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1056\/NEJMoa0809003","article-title":"Denosumab in men receiving androgen-deprivation therapy for prostate cancer","volume":"361","author":"Smith","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beem.2018.05.007_bib81","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1359\/jbmr.090716","article-title":"Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy","volume":"25","author":"Kendler","year":"2010","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.beem.2018.05.007_bib82","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","article-title":"10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension","volume":"5","author":"Bone","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.beem.2018.05.007_bib83","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1002\/jbmr.3110","article-title":"Clinical features of 24 patients with rebound-associated vertebral fractures after denosumab discontinuation: systematic review and additional cases","volume":"32","author":"Anastasilakis","year":"2017","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.beem.2018.05.007_bib84","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1359\/jbmr.2003.18.1.9","article-title":"The effect of teriparatide (human parathyroid hormone 1-34) therapy on bone density in men with osteoporosis","volume":"18","author":"Orwoll","year":"2003","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.beem.2018.05.007_bib85","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1001\/jama.2016.11136","article-title":"Effects of abaloparatide on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial","volume":"316","author":"Miller","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.beem.2018.05.007_bib86","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1002\/jbmr.1768","article-title":"The US postmarketing surveillance study of adult osteosarcoma and teriparatide: study design and findings from the first 7 years","volume":"27","author":"Andrews","year":"2012","journal-title":"J\u00a0Bone Miner Res"},{"issue":"386","key":"10.1016\/j.beem.2018.05.007_bib87","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(15)61120-5","article-title":"Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised, controlled trial","volume":"19","author":"Leder","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.beem.2018.05.007_bib88","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1007\/s00198-004-1713-3","article-title":"Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy","volume":"16","author":"Kaufman","year":"2005","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.beem.2018.05.007_bib89","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.1002\/art.24879","article-title":"Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: 36 month results","volume":"60","author":"Saag","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.beem.2018.05.007_bib90","doi-asserted-by":"crossref","first-page":"711","DOI":"10.7326\/M14-0317","article-title":"Comparative effectiveness of pharmacologic treatments to prevent fractures: an updated systematic review","volume":"161","author":"Crandall","year":"2014","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.beem.2018.05.007_bib91","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1001\/jama.2017.19344","article-title":"Association between calcium or vitamin D supplementation and fracture incidence in community-dwelling older adults: a systematic review and meta-analysis","volume":"318","author":"Zhai","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.beem.2018.05.007_bib92","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/BOR.0000000000000300","article-title":"Determinants of mortality risk following osteoporotic fractures","volume":"28","author":"Bliuc","year":"2016","journal-title":"Curr Opin Rheumatol"}],"container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X18300757?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X18300757?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T16:52:54Z","timestamp":1761497574000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521690X18300757"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":92,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["S1521690X18300757"],"URL":"https:\/\/doi.org\/10.1016\/j.beem.2018.05.007","relation":{},"ISSN":["1521-690X"],"issn-type":[{"value":"1521-690X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Update on osteoporosis in men","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Endocrinology & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beem.2018.05.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}